# Zydus Lifesciences 表示將以總價 1.66 億美元收購美國製藥公司 Assertio Holdings。

*biotech, business · news · 2026-05-13 · Moneycontrol*

## Key points

- Zydus Lifesciences 將以 1.664 億美元現金收購美國 Assertio Holdings。
- 此次收購讓 Zydus 透過 Assertio 獲得成熟的美國專科腫瘤商業平台。
- Zydus 將發起對 Assertio 股份的公開收購要約，隨後進行第二階段合併。
- 該交易預計於 2026-27 財政年度完成，需符合標準條件。

Zydus Lifesciences on Wednesday said it will acquire US-based pharma firm Assertio Holdings for a total consideration of USD 166.4 million (approximately Rs 1,590 crore). Zydus Worldwide DMCC, a subsidiary of the company, has signed a definitive agreement, through its wholly-owned acquisition arm Zara Merger Sub Inc, with Assertio Holdings Inc to acquire all outstanding shares of Assertio for USD 23.50 per share in cash, Zydus Lifesciences Ltd said in a statement. It represents total consideration of approximately USD 166.4 million on a fully-diluted basis, calculated using the treasury stock method, it added. Assertio is a US-based pharmaceutical company focused on speciality and oncology supportive-care therapies. The acquisition provides Zydus with an established US speciality oncology commercial platform, anchored by Assertio's presence in oncology supportive care, the statement said. "This transaction represents a strategic step in strengthening our speciality and oncology footprint in the US. Assertio brings a focused commercial platform and an approved oncology asset that aligns well with our long-term strategy of building differentiated, durable speciality businesses globally," Zydus Lifesciences MD Sharvil P Patel said. Zydus said it intends to leverage Assertio's focused commercial infrastructure and oncology relationships to build and expand its speciality oncology presence in the US. Under the terms of the merger agreement, Zydus will commence a tender offer to acquire all outstanding shares of Assertio common stock. The transaction is structured as a tender offer to be followed by a merger, subject to customary closing conditions, including the tender of shares representing at least a majority of the total number of outstanding shares of Assertio common stock, the statement said. After the successful completion of the tender offer, Zydus will acquire all remaining shares not tendered in the tender offer through a second-step merger at the same price paid in the tender offer, it added. The tender offer is expected to commence within five business days, following the date of the merger agreement, the company said. The transaction is expected to close in the financial year 2026-27, subject to satisfaction of all closing conditions, Zydus Lifesciences said.

**Companies:** Zydus Lifesciences, Assertio Holdings
**Countries:** United States, India

[Read the full story on Moneycontrol](https://www.moneycontrol.com/news/business/zydus-buys-us-pharma-firm-assertio-for-rs-1-590-crore-to-deepen-oncology-push-in-america-13918413.html)

---

Canonical: https://newsio.io/zh-TW/n/0bb15099-58bf-45fd-930d-19d9ebdbf245/zydus-lifesciences-1-66-assertio-holdings
Summarized by Newsio from Moneycontrol. https://newsio.io/how-it-works